NASDAQ:OMTH Omthera Pharmaceuticals (OMTH) Stock Price, News & Analysis → The only accurate crypto trading system I know … (From Weiss Ratings) (Ad) Free OMTH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Omthera Pharmaceuticals alerts: Email Address Ad Stansberry ResearchFed launches fourth dollar overhaulYou've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???Just click here now for the full story. About Omthera Pharmaceuticals Stock (NASDAQ:OMTH)Omthera Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, its product candidate, is a late-stage, omega-three free fatty acid composition that reduces triglycerides, improves other key lipid parameters. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-three and omega-six fatty acids, with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid being the most abundant forms of omega-three fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova.Read More Ad Stansberry ResearchFed launches fourth dollar overhaulYou've likely heard a million different warnings about the changes taking place in America's financial system right now... How the White House plans to take the dollar fully digital???Just click here now for the full story. OMTH Stock News HeadlinesJanuary 8, 2024 | businesswire.comNanoPhoria appoints Dr. Suman Shirodkar as Chair and Prof. Michael Davidson as Non-Executive Member of the Board of DirectorsOctober 14, 2021 | finance.yahoo.comAbcentra Appoints Entrepreneur and Cardiologist Michael H. Davidson to Board of DirectorsApril 25, 2024 | Behind the Markets (Ad)Will this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!September 12, 2021 | finance.yahoo.comGlobal Cardiovascular Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021See More Headlines Receive OMTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:OMTH CUSIPN/A CIKN/A Webwww.omthera.com Phone+1-908-7414323FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report OMTH Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Omthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omthera Pharmaceuticals investors own include Scorpio Tankers (STNG), Avon Products (AVP), Corcept Therapeutics (CORT), Ceragon Networks (CRNT), Direxion Daily CSI China Internet Index Bull 2x Shares (CWEB), Cypress Semiconductor (CY), Denali Therapeutics (DNLI) and Invitae (NVTA). This page (NASDAQ:OMTH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omthera Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
